The effectiveness of creatine treatment for Parkinson’s disease: an updated meta-analysis of randomized controlled trials

Jia-Jie Mo 1,2†, Lin-Ying Liu 3†, Wei-Bin Peng 4, Jie Rao 5, Zhou Liu 1,2* and Li-Li Cui 1*

Abstract

Background: The effectiveness of creatine in treating Parkinson’s disease (PD) has not been conclusively determined. Therefore, we performed a meta-analysis to address this issue.

Methods: The Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, and other databases were searched, and outcomes measured by the Total Unified Parkinson’s Disease Rating Scale (UPDRS) and the Schwab & England Scale were analyzed.

Results: Five randomized controlled trials (RCTs) were selected, and 1339 participants were included in the analysis. There were no significant differences between the control and treatment groups in the total, mental, activities of daily living (ADL), or motor UPDRS scores, but an improvement in Schwab & England Scale scores was observed.

Conclusions: Creatine has no observed benefit in PD patients, although more correlated studies are still needed.

Keywords: Creatine, Meta-analysis, Mitochondrial dysfunction, Parkinson’s disease

Background

Parkinson’s disease (PD) is a common, progressive, neurodegenerative condition that causes both motor (stiffness, slowness, rest tremor, and poor postural reflexes) and non-motor symptoms (abnormalities in mood, cognition, sleep, and autonomic function). The incidence of PD ranges from 8 to 18 per 100,000 person-years [1], and thus identifying effective drugs that can slow the progression of PD is critical. PD is not purely a disorder of the basal ganglia; it also has systemic causes. For instance, a variety of mechanisms including oxidative stress, excitotoxicity, apoptosis, and mitochondrial dysfunction can all contribute to PD [2, 3]. Additionally, disease pathogenesis results not only from the loss of dopaminergic neurons in the substantia nigra pars compacta but also from deposits of α-synuclein in the peripheral nervous system and deterioration of small nerve fibers [4]. Existing drugs such as levodopa, dopamine agonists, monoamine oxidase inhibitors (MAO-B inhibitors), and catechol-O-methyltransferase inhibitors (COMT inhibitors) are not completely effective in PD patients. Therefore, neuroprotective agents such as creatine have increasingly been considered for their potential efficacy [5–9].

Creatine is a natural compound that plays an important role in cellular energy homeostasis. It can be converted to phosphocreatine [10], an energy intermediate that can then transfer a phosphoryl group to synthesize mitochondrial ATP. Creatine exhibits anti-apoptotic, anti-excitotoxic and direct antioxidative properties [5]. Previous studies have reported that homocysteine accumulation may eventually lead to peripheral nerve damage [11, 12] and that creatine exhibits neuroprotective and antioxidant properties [13] by reducing homocysteine levels [14]. Therefore, creatine may be effective in treating neurodegenerative diseases [15–17].

Previous studies have reported conflicting results regarding the effect of creatine as a treatment for PD, and it remains unclear whether creatine treatment can improve clinical outcomes when compared with a placebo [18–22]. Therefore, this meta-analysis was conducted to
investigate the symptomatic efficacy of creatine versus placebo, analyzing outcomes assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Schwab & England Activities of Daily Living Scale.

Methods

Literature search
Two authors independently conducted a systematic literature search of multiple databases, including the Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, and other sources, for studies published through October 2016. We also searched internet-based clinical trial registries, such as the clinical trial registry (Clinicaltrials.gov) and the OpenGrey database (a system for information on the gray literature in Europe). The following keywords and MeSH terms were used: “creatine”, “Parkinson’s disease”, and “randomized controlled trials”.

Study selection
Trials were included in our meta-analysis if they met all the following criteria: (1) they were randomized, double-blinded, controlled trials (RCTs); (2) the recruited patients met the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria and their PD-MCI diagnosis was based on the Criteria for the Diagnosis of PD-MCI [23] formulated by the Movement Disorder Society (MDS) of the United States; (3) the intervention therapies included creatine; and (4) the efficacy was assessed by the UPDRS or the Schwab & England Scale. Two of the authors independently applied these selection criteria to screen studies for eligibility.

Data extraction
The data were collected in two steps. First, the title and abstract of each study were recorded, and studies that were either clearly irrelevant or were duplicates were removed. Second, the full text of articles that passed the initial screening was retrieved, and the eligibility of these studies for this meta-analysis was determined after collecting the following information: last name of the first author, year of publication, study design details, methodological quality (assessed using domain-based evaluations [Cochrane Handbook 8.3.1]), patient characteristics (including gender, age, disease duration, and baseline disease severity), sample size, treatment dose, duration of treatment, and study outcomes (changes in Mental UPDRS, activities of daily living (ADL) UPDRS, Motor UPDRS, Total UPDRS or Schwab & England scores). Multiple authors were involved in the screening, and any disagreements regarding eligibility were resolved through careful discussion.

Quality assessment
Two authors independently assessed the validity of each study by determining the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0) [24]. Any disagreements in the authors’ assessments were resolved through discussion. Specifically, the studies were evaluated considering the following criteria: random sequence generation, allocation sequence concealment, blinding of outcome assessment, incomplete outcome data and other latent threats to validity. The risk of bias was categorized as “high”, “unclear” or “low”.

Level of evidence
We determined the quality of evidence in each study using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. GRADE profiler 3.6 software (Cochrane Collaboration, http://tech.cochrane.org/revman/other-resources/gradepro/download) was used to create an evidence profile, and each study was characterized as follows: (1) high quality (A), indicating that further research was extremely unlikely to change our confidence in the estimate of effect; (2) moderate quality (B), indicating that further research was likely to have an important impact on our effect estimate and could change the estimate; (3) low quality (C), indicating that further research was extremely likely to have an important impact on our effect estimate and could change the estimate; and (4) very low quality (or D), indicating that we were extremely uncertain about the estimate of effect.

Statistical analysis
The data analyses were performed using Review Manager Software (Version 5.3). The mean changes from baseline in the UPDRS scores and the Schwab & England Scale scores were treated as continuous variables, and the weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated as the difference between the effects of creatine and placebo treatment. Heterogeneity, assessed by the standard Cochran Q and I-squared measures, was determined by \( P < 0.10 \) or I-squared >50% in each study. When there was homogeneity between trials, a fixed-effect model approach was used to combine the trial outcomes [25], while a random-effects model was used in cases of heterogeneity [26].

Results

Search results and study characteristics
The search strategy initially identified 302 articles published prior to October 2016. Twenty-three of these articles were selected, and the full papers were analyzed to assess the efficacy and safety of creatine treatment in PD patients. Of these 23 papers, 17 were excluded and 1
was incomplete, although it may have satisfied the inclusion criteria [27], leaving 5 studies available for the final analysis [[18–22]; Fig. 1]. The main characteristics of the included studies and patient populations are summarized in Table 1 and Table 2, respectively. In one study, creatine was administered at a loading dose of 20 g/d for 6 days, followed by 2 g/d for 6 months and finally 4 g/d for 2 years [21]. Another study combined creatine (10 g/d) with coenzyme Q10 (300 mg/d) [18]. Patients in the other 3 studies all received 10 g/d of creatine [19, 20, 22]. Disease progression was primarily measured using the UPDRS. Three of the five studies assessed disease progression using the Total, Mental, ADL, and Motor UPDRS scores. One study used the Total UPDRS scores only [20], and one study used the UPDRS Motor scores only [18]. Two studies provided data based on the Schwab & England scale [19, 22]. The assessment of risk of bias among included studies was shown in the Fig. 2. The meta-analyses of the studied outcomes were shown in the Fig. 3.

The effect of Creatine vs. placebo treatment on Total UPDRS scores
Four of the trials included in this analysis reported data on the effects of creatine vs. placebo on Total UPDRS scores [19–22]. As shown in Table 3, the pooled WMD of the Total UPDRS scores at the end of the follow-up period in patients who received creatine compared to those who received placebo was −0.39 (95% CI = [−2.63, 1.85], \( P = 0.73 \)), with no significant heterogeneity (\( P = 0.13, I^2 = 47\% \)); this finding indicating that creatine treatment did not affect PD patients’ Total UPDRS scores differently than placebo.

Table 1 Characteristics of the studies included in the meta-analysis

| Author         | Year | Method | Country | Participants | Intervention(s)                                      | Outcomes                                      |
|----------------|------|--------|---------|--------------|-----------------------------------------------------|------------------------------------------------|
| NINDS [22]     | 2006 | RCT    | USA     | 67           | Control: Creatine 10 g/d and Minocycline 200 mg/d   | Total UPDRS scores; UPDRS I/II/III             |
| Bender [21]    | 2006 | RCT    | Germany | 40           | Control: Creatine 4 g/d                              | Total UPDRS scores; UPDRS I/II/III             |
| NINDS [20]     | 2008 | RCT    | USA     | 64           | Control: Creatine 10 g/d                              | Total UPDRS scores                             |
| Kieburz [19]   | 2015 | RCT    | Canada/USA | 477          | Control: Creatine 10 g/d                              | Total UPDRS scores; UPDRS I/II/III Schwab & England Scale |
| Li [18]        | 2015 | RCT    | China   | 38           | Control: Creatine 10 g/d and Coenzyme Q10 300 mg/d   | UPDRS III Schwab & England Scale              |

RCT Randomized controlled trial, UPDRS Unified Parkinson’s Disease Rating Scale
The effect of Creatine vs. placebo treatment on UPDRS mental scores

In three of the five studies [19, 21, 22], UPDRS Mental scores were also used to assess the effects of creatine vs. a placebo in patients with PD (Table 3). The pooled WMD for UPDRS Mental scores at the end of the follow-up period in patients who received creatine compared to those who received placebo was -0.46 (95% CI = [-1.20, 0.29], P = 0.23) and was associated with statistically significant heterogeneity (P = 0.0005, I² = 87%).

| Author          | Intervention(s) | Total UPDRS score | UPDRS Mental score | UPDRS ADL score | UPDRS Motor score | Hoehn & Yahr scale | Schwab & England scale | Follow-up Duration (months) | Disease Duration (years) |
|-----------------|-----------------|-------------------|--------------------|-----------------|-------------------|--------------------|------------------------|--------------------------|--------------------------|
| NINDS 2006 [22] | Creatine 10 g/d  | 23.9(9.07)        | 1.13(1.29)         | 6.32(3.07)      | 16.4(6.77)        | 1.43(0.5)          | 92.7(5.25)             | 12                       | Within 5 yrs             |
|                 | Placebo         | 22.8(9.63)        | 1.13(1.19)         | 6.03(3.45)      | 15.6(7.01)        | 1.46(0.5)          | 94.2(4.81)             |                          |                          |
| Bender 2006 [21]| Creatine 4 g/d  | 27.4(11.7)        | 2.2(1.9)           | 8.1(4.6)        | 16.3(7.0)         |                   |                        | 24                       | Above 2 yrs              |
|                 | Placebo         | 27.4(11.7)        | 1.6(1.5)           | 7.8(4.8)        | 17.4(1.1)         |                   |                        |                          |                          |
| NINDS 2008 [20] | Creatine 10 g/d | 23.9(9.07)        | 1.13(1.29)         | 6.33(3.07)      | 16.4(6.77)        | 1.43(0.5)          | 92.7(5.25)             | 18                       | Within 5 yrs             |
|                 | Placebo         | 22.8(9.63)        | 1.13(1.19)         | 6.03(3.45)      | 15.6(7.01)        | 1.46(0.5)          | 94.2(4.81)             |                          |                          |
| Kieburtz 2015 [19] | Creatine 10 g/d | 26.5(11.7)        | 1.3(1.4)           | 7.3(4.1)        | 17.9(8.6)         |                   |                        | 60                       | Within 5 yrs             |
|                 | Placebo         | 25.9(11)          | 1.3(1.4)           | 7.0(3.8)        | 17.6(8.1)         |                   |                        |                          |                          |
| Li 2015 [18]    | Creatine 10 g/d |                   | 17.5(7.8)          |                |                   |                   |                        | 18                       | Approximately 7.7 yrs    |
|                 | Placebo         | 18.8(7.4)         |                   |                |                   |                   |                        |                          |                          |

Values: weighted mean difference (standard deviation)

The effect of Creatine vs. placebo treatment on UPDRS ADL scores

Data on the effect of creatine vs. placebo treatment on UPDRS ADL scores were reported in three studies [19, 21, 22]. As described in Table 3, the pooled WMD for the scores at the end of the follow-up period in patients who received creatine compared to those who received placebo was 0.39 (95% CI = [-0.38, 1.17], P = 0.32), with non-significant heterogeneity (P = 0.21, I² = 37%), indicating that creatine treatment and placebo had similar effects on PD patients’ UPDRS ADL scores.

Fig. 2 Assessing the risk of bias of the included studies. (a) A summary of the authors’ evaluation of the risk of bias criteria for each included study; (b) A graph of the authors’ evaluation of each risk of bias criterion presented as percentages across all included studies.
Fig. 3 The effect of creatine treatment versus placebo. (a) Change in Total UPDRS scores from baseline; (b) Change in UPDRS Mental scores; (c) Change in UPDRS ADL scores; (d) Change in UPDRS Motor scores; (e) Change in Schwab & England Scale scores

| Study or Subgroup | Experimental | Control | Mean Difference | Weight |
|-------------------|--------------|---------|----------------|--------|
|                   | Mean | SD  | Total | Mean | SD  | Total |       |        | IV, Random, 95% CI |
| Bender 2006       | 3.9  | 7.66| 40    | 1.4  | 10.22| 20    | 14.2% | 2.50  | [-2.89, 7.60]     |
| Kieburz 2015      | 11.3 | 15.3| 477   | 10.4 | 13.8 | 478   | 39.6% | 0.90  | [0.95, 2.75]      |
| NINDS 2006        | 5.6  | 8.69| 67    | 8.39 | 9.76 | 67    | 26.3% | -2.70 | [-5.92, 0.34]     |
| NINDS 2008        | 6.18 | 11.4| 64    | 8.03 | 11.5 | 63    | 19.9% | -1.86 | [-5.83, 2.13]     |
| Total (95% CI)    | 648  | 628 | 100.0%|       |        |        |       |        | -0.39 [-2.63, 1.85] |
| Heterogeneity: Tau² = 2.41; Chi² = 5.70, df = 3 (P = 0.13); I² = 47% |
| Test for overall effect: Z = 0.34 (P = 0.73) |

| Study or Subgroup | Experimental | Control | Mean Difference | Weight |
|-------------------|--------------|---------|----------------|--------|
|                   | Mean | SD  | Total | Mean | SD  | Total |       |        | IV, Random, 95% CI |
| Bender 2006       | -0.3 | 1.14| 40    | 0.8  | 1.09 | 20    | 31.3% | -1.10 | [-1.69, -0.51]    |
| Kieburz 2015      | 1.2  | 1.9 | 477   | 1.1  | 1.8  | 478   | 37.6% | 0.10  | [-0.13, 0.33]     |
| NINDS 2006        | 0.33 | 1.66| 67    | 0.81 | 1.87 | 67    | 31.2% | -0.48 | [-1.08, 0.12]     |
| Total (95% CI)    | 584  | 565 | 100.0%|       |        |        |       |        | -0.46 [-1.20, 0.29] |
| Heterogeneity: Tau² = 0.37; Chi² = 15.21, df = 2 (P = 0.0005); I² = 87% |
| Test for overall effect: Z = 1.20 (P = 0.25) |

| Study or Subgroup | Experimental | Control | Mean Difference | Weight |
|-------------------|--------------|---------|----------------|--------|
|                   | Mean | SD  | Total | Mean | SD  | Total |       |        | IV, Random, 95% CI |
| Bender 2006       | 1.4  | 2.85| 40    | 0.1  | 2.9  | 20    | 19.3% | 1.30  | [-0.25, 2.85]     |
| Kieburz 2015      | 4.5  | 5.7 | 477   | 4.5  | 5.1  | 478   | 51.5% | 0.50  | [-0.19, 1.19]     |
| NINDS 2006        | 2.21 | 3.09| 67    | 2.6  | 3.74 | 67    | 29.2% | -0.39 | [-1.55, 0.77]     |
| Total (95% CI)    | 584  | 565 | 100.0%|       |        |        |       |        | 0.39 [-0.38, 1.17] |
| Heterogeneity: Tau² = 0.18; Chi² = 3.16, df = 2 (P = 0.21); I² = 37% |
| Test for overall effect: Z = 1.00 (P = 0.32) |

| Study or Subgroup | Experimental | Control | Mean Difference | Weight |
|-------------------|--------------|---------|----------------|--------|
|                   | Mean | SD  | Total | Mean | SD  | Total |       |        | IV, Random, 95% CI |
| Bender 2006       | 2.6  | 5.22| 40    | 0.4  | 3.78 | 20    | 9.6%  | 2.20  | [-1.81, 6.21]     |
| Kieburz 2015      | 5.6  | 10.2| 477   | 5.3  | 9.8  | 478   | 44.2% | 0.30  | [-0.97, 1.57]     |
| LI 2015           | 1.8  | 5.07| 38    | 1.8  | 5.14 | 37    | 22.9% | 0.00  | [-2.31, 2.31]     |
| NINDS 2006        | 3.27 | 6.65| 67    | 5.34 | 6.92 | 67    | 23.3% | -2.07 | [-4.35, 0.21]     |
| Total (95% CI)    | 622  | 602 | 100.0%|       |        |        |       |        | -0.14 [-1.47, 1.19] |
| Heterogeneity: Tau² = 0.63; Chi² = 4.52, df = 3 (P = 0.21); I² = 34% |
| Test for overall effect: Z = 0.20 (P = 0.84) |

| Study or Subgroup | Experimental | Control | Mean Difference | Weight |
|-------------------|--------------|---------|----------------|--------|
|                   | Mean | SD  | Total | Mean | SD  | Total |       |        | IV, Random, 95% CI |
| Kieburz 2015      | 16.8 | 28.3| 477   | 14.8 | 26   | 478   | 34.9% | 2.00  | [1.45, 5.45]      |
| NINDS 2006        | -4.8 | 6.12| 67    | -7.6 | 8.59 | 67    | 66.1% | 2.80  | [0.27, 5.33]      |
| Total (95% CI)    | 544  | 545 | 100.0%|       |        |        |       |        | 2.52 [0.48, 4.56] |
| Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 1 (P = 0.71); I² = 0% |
| Test for overall effect: Z = 2.42 (P = 0.02) |
The effect of Creatine vs. placebo treatment on UPDRS motor scores

Four of the studies [18, 19, 21, 22] explored the effects of creatine vs. placebo treatment on UPDRS Motor scores (Table 3) and found that the pooled WMD for UPDRS Motor scores at the end of the follow-up period in patients who received creatine compared to those who received placebo was −0.14 (95% CI = [−1.47, 1.19], P = 0.84), with non-significant heterogeneity (P = 0.21, I² = 34%). This result suggested that creatine treatment did not have a greater effect than placebo on PD patients.

The effect of Creatine vs. placebo treatment on Schwab & England Scale scores

Two of the studies examined here [19, 22] explored the effects of creatine vs. placebo treatment on Schwab & England Scale scores (Table 3). The pooled WMD of Schwab & England Scale scores at the end of the follow-up period in patients who received creatine compared to those who received placebo was 2.52 (95% CI = [0.48, 4.56], P = 0.02), and the results showed statistically significant heterogeneity (P = 0.71, I² = 0%). These findings indicated that PD patients who used creatine may have had a higher Schwab & England Scale score than those who received the placebo.

Risk of bias in the included studies

The risk of bias of each parameter in each study was also assessed (Fig. 2). One study [19] reported a high drop-out rate (greater than 20%), and this attrition bias posed a high risk. Overall, no studies were deemed completely free of risk of bias. We also assessed the quality of evidence in each study using the GRADE scale (Table 4).

Discussion

In our meta-analysis of five previously published papers, we assessed the effectiveness of creatine treatment versus placebo in PD patients. We found no association between creatine treatment and a decreased Total, Mental, ADL, or Motor UPDRS score, but we did note a greater improvement in Schwab & England Scale scores with use of creatine compared to placebo; however, this last test was included in 2 studies only. Both the UPDRS ADL and the Schwab & England Scale assess whether patients show improvement in ADL; however, this analysis indicated conflicting outcomes. Therefore, we believe that not enough evidence exists to support the theory that creatine can enhance ADL.

Conventional medications have been ineffective in curing PD to date, and creatine treatment has emerged as a potential method for slowing the progression of PD. Correlated basic studies have suggested that creatine does have a positive effect on PD patients, and these initial results led to the initiation of multiple clinical trials [18–22]. However, consensus has not been reached on whether this treatment is effective, which is what prompted this meta-analysis. Our findings may provide clinicians with an alternative approach to treating PD. Although another meta-analysis on this subject was performed by Xiao et al. (2014) [28] and involved two RCTs with a total of 194 patients, the findings were unreliable because of the high risk of bias, the small sample sizes and the short duration of the eligible trials. The efficacy of creatine treatment for PD requires data from clinical trials before any conclusions can be reached. The systematic review conducted here assessed the efficacy and safety of creatine as a primary or adjuvant treatment for PD. We included five RCTs [18–22] that had a total of 1339 patients and compared creatine treatment with the administration of a placebo. To evaluate the PD patients’ prognosis, we assessed whether their UPDRS scores or Schwab & England Scale scores had changed after treatment. We addressed the limitations of the previous meta-analysis by performing a comprehensive and extensive literature search that evaluated RCTs using appropriate criteria, including a qualitative analysis of RCTs and the use of the GRADE approach to determine the quality of evidence. The quality of the studies was considered only moderate or low based on the following parameters: [1] the included trials were reported as randomized, double-blind trials but did not provide additional details; [2] moderate variation in baseline variables was observed among the studies; [3] some comparisons exhibited heterogeneity; and [4] creatine was used in combination with CoQ10 or minocycline [18, 22]. The RCTs were generally of high quality, although we did include RCTs that involved diverse risks. Overall, the methodological quality of the 5 enrolled studies was considered good with respect to the most common and relevant biases.
Table 4 GRADE evidence profile for all included studies

| Outcomes                      | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) |
|-------------------------------|----------------------------------------|--------------------------|------------------------------|--------------------------------|
| **Total UPDRS scores**       |                                        | WMD = -0.67              | 987                          | Low 1, 2, 3, 6                  |
| Follow-up: mean 25.5 months  | The mean Total UPDRS scores among the intervention groups was 0.67 lower (2.87 lower to 1.53 higher) | (-2.87 to 1.53)          | (4 studies)                  |                                |
| **UPDRS Mental score**       |                                        | WMD = -0.18              | 866                          | Low 1, 3, 6                    |
| Follow-up: mean 28 months    | The mean UPDRS Mental score among the intervention groups was 0.18 lower (0.63 lower to 0.27 higher) | (-0.63 to 0.27)          | (3 studies)                  |                                |
| **UPDRS ADL scores**         |                                        | WMD 0.58                 | 866                          | Moderate 1, 5                  |
| Follow-up: mean 28 months    | The mean UPDRS ADL score among the intervention groups was 0.58 higher (0.19 lower to 1.36 higher) | (-0.19 to 1.36)          | (3 studies)                  |                                |
| **UPDRS Motor scores**       |                                        | WMD = 0.06               | 1009                         | Low 1, 4, 6                    |
| Follow-up: mean 25.5 months  | The mean UPDRS Motor score among the intervention groups was 0.06 lower (1.67 lower to 1.55 higher) | (-1.67 to 1.55)          | (4 studies)                  |                                |
| **Schwab & England scale**   |                                        | WMD = -0.55              | 1089                         | Low 1, 5, 6                    |
| Follow-up: mean 30 months    | The mean Schwab & England scale score among the intervention groups was 0.55 lower (5.24 lower to 4.15 higher) | (-5.24 to 4.15)          | (2 studies)                  |                                |

*Basis for the assumed risk (e.g., the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval

GRADE Working Group categories for quality of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate of effect

1 Evidence includes lack of allocation concealment and random sequence generation
2 A moderate variation in baseline variables between trials
3 The p value for heterogeneity was greater than 0.05, and I^2 was 50% in the comparison of four studies; however, the quality of the evidence was not downgraded because it was considered low risk
4 Two trials [18, 22] used creatine combined with CoQ10 or minocycline as a co-intervention. The intervention was not confined to a single variation, which may induce an indirect influence
5 The p value for heterogeneity was less than 0.05, and I^2 was 79% in this comparison with 2 studies. The quality of the evidence was downgraded for inconsistency
6 The rate of drop-outs in the trial [19] was high and greater than 20% (397/894 in the creatine group and 289/867 in the placebo group)
Because the high number of patients enrolled in the study by Kieburtz et al. [19] accounted for a large proportion of our overall analytical sample (955/1339; 71.3%), a sensitivity analysis was performed and found no evidence of significant heterogeneity. We found that this single study did influence the overall outcome, resulting in a significant decline in UPDRS Mental scores. Although a sensitivity analysis was performed and found no evidence of significant heterogeneity. This influence might be due to the large sample size, the longer follow-up duration or the high rate of drop-outs that had to be excluded. These and other confounding factors, such as follow-up duration, disease duration, and the baseline disease severity of the patients in each study, are fully described in Table 2. The baseline characteristics of the patient population were similar when initially assessed. Regarding follow-up duration, only the study by Kieburtz et al. [19] lasted longer than 24 months. This parameter, together with the high rate of drop-outs in that same study, may account for the heterogeneity observed when examining the UPDRS Mental scores. Additionally, the disease duration in the study by Li et al. [18] was longer than the duration reported in the other 4 studies, and this discrepancy may or may not have contributed to the significant heterogeneity observed.

There are some limitations to this meta-analysis. First, although we included three more studies than Xiao et al. (2014), the per-study and overall sample size remained small. Second, the disease outcomes were primarily assessed by the UPDRS and Schwab & Englund Scale, which may not cover other potential treatment benefits for patients with psychiatric and cognitive disorders. Finally, these studies lacked long-term assessments of key indicators, such as 5- or 10-year patient survival rates. Some of the trials were quite heterogeneous, with several reasonable explanations for this finding: [1] the trials used different doses of creatine; [2] two of the trials [18, 22] used CoQ10 or minocycline as a co-intervention; [3] all of the trials were reported as RCTs but did not provide additional details; [4] the intervention was not confined to a single variant, which may have had indirect effects; and [5] one study [19] reported a high drop-out rate (greater than 20%).

Based on this meta-analysis, we believe that creatine treatment is ineffective and that it has limited prospects as a drug of choice for PD. The limited efficacy of creatine in treating PD can be explained by several factors. First, the cellular transport of this substance is constrained [29]. In a previous study, after patients were treated with creatine (3.4 g/d) for 4 weeks, brain creatine levels were only slightly elevated [30]. Another factor is the insufficient dose administered. Compared to rodents, which were given 4 g of creatine per day in their food (133 g/kg), humans who received the highest dose of 10 g of creatine per day (0.15 g/kg for a 65-kg adult) still did not experience the same positive effects [21]. Moreover, in a study that involved mitochondrial dysfunction, creatine was found to be significantly correlated with depression [31]. One study we included in this analysis found that patients treated with creatine had a significantly better score on the Mental UPDRS (P = 0.046) [21], while another found that creatine combined with Coenzyme Q10 could delay the decline in cognitive function of patients with PD, as assessed by the Montreal Cognitive Assessment (MoCA) [18]. Thus, in addition to focusing on the efficacy of creatine in relieving the motor symptoms of PD, we should also examine its effect on the psychiatric and cognitive symptoms.

Although the effectiveness of creatine in improving mitochondrial function has previously been demonstrated, it showed no effect on PD patients in this analysis. Accordingly, we hypothesize that mitochondrial dysfunction may play an indirect role in the development of PD, which may be susceptible to many other underlying but yet unknown factors. Therefore, the use of other neuroprotective agents to treat PD should still be investigated.

**Conclusion**

Creatine was not found to be effective in treating patients with PD, although more evidence is needed to determine whether it can improve their ADL. In addition, future studies that determine whether the drug might be useful in treating psychiatric and cognitive disorders should be conducted.

**Abbreviations**

95%CI: 95% confidence interval; ADL: Activities of daily living; PD: Parkinson’s disease; RCT: Randomized controlled trial; UPDRS: Unified Parkinson’s Disease Rating Scale; WMD: Weighted mean differences

**Acknowledgments**

We would like to thank ZL for the excellent technical support.

**Funding**

This work was supported by funding from the National Natural Science Foundation of China (No. 81400986), the Natural Science Foundation of Guangdong Province (No. 2014A030313541), the Science and Technology Planning Project of Zhanjiang (No. 2014A01031), and the Project of Dongguan (No. 2013508152012). The funding agencies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

All data are fully available without restriction.

**Authors’ contributions**

ZL and LLC conceived and designed the study. WBP and JR performed the selection of studies, data-extraction. LYL and JJM drafted the review. ZL and JJM carried out the statistical analysis and interpretation of data. All authors participated in revising the manuscript and the final approval of the manuscript.

**Competing interests**

None of the authors received financial support from companies, organizations, or other entities that may have affected the interpretation of the data. No financial conflicts of interest exist.
Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, No.2 Wenming Road, Zhanjiang, Guangdong 524023, People’s Republic of China. 2Department of Neurology, Affiliated Hospital of Guangdong Medical University, No.2 Wenming Road, Zhanjiang, Guangdong 524023, People’s Republic of China. 3Department of Neurology, Chenzhou No.1 People’s Hospital, Chenzhou, People’s Republic of China. 4Graduate School, Guangzhou Medical University, Guangzhou City, People’s Republic of China. 5Department of Pathology, People’s Hospital of Wuhan University, Wuhan City, People’s Republic of China.

Received: 7 November 2016 Accepted: 18 May 2017
Published online: 02 June 2017

References
1. Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin. 2016; 34(4):955–65.
2. Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, et al. Caffeine and progression of Parkinson disease: a deleterious interaction with Creatine. Clin Neuropharmacol. 2015;38(5):163–9.
3. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology. 2003;60(8):1234–40.
4. Comi C, Magistrelli L, Oggoni GD, Careccchio M, Fleetwood T, Cantello R, et al. Peripheral nervous system involvement in Parkinson’s disease: evidence and controversies. Parkinsonism Relat Disord. 2014;20(12):1329–34.
5. Lewitt PA. Clinical trials of neuroprotection for Parkinson’s disease. Neurology. 2004;63(2):23–31.
6. Takubo H, Shimoda-Matsubayashi S, Mizuno Y. Serum creatine kinase is elevated in patients with Parkinson’s disease: a case controlled study. Parkinsonism Relat Disord. 2003;9(Suppl 1):S543–6.
7. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurologial and atherosclerotic disease? Neuroscience. 2002;112(2):243–60.
8. Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly.Curr Opin Clin Nutr Metab Care. 2000;3(6):497–502.
9. Shimoda-Matsubayashi S, Yagi K, Tanabe H. [the elevation of serum creatine kinase in the course of Parkinson disease—in relation to malignant syndrome]. Rinsho shinkeigaku =. Clinical neurology. 1996;36(8):935–9.
10. Bender A, Klopstock T. Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. 2016;48(8):1–12.
11. Bereket-Yucek S. Creatine supplementation alters homocysteine level in resistance trained men. J Sports Med Phys Fitness. 2015;55(4):313–9.
12. Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochem Biophys Res Commun. 2002;290(1):47–52.
13. Sakly G, Hellara O, Trabelsi A, Dogui M. Reversible peripheral neuropathy induced by vitamin B12 deficiency. Neurophysiol Clin. 2005;35(5–6):149–53.
14. Puri V, Chaudhry N, Goel S, Gulati P, Nehru R, Chowdhury D. Vitamin B12 deficiency: a clinical and electrophysiological profile. Electromyogr Clin Neurophysiol. 2005;45(5):273–84.
15. Allen PJ. Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value? Neuropsy Biobehav Rev. 2012;36(5):1442–62.
16. Klein AM, Ferrante RJ. The neuroprotective role of creatine. Subcell Biochem. 2007;46:205–43.
17. Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21(2):107–15.
18. Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson’s disease. Eur Neurol. 2015;73(3–4):205–11.
19. Kieburz K, Tilley BC, Elm JB, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584–93.
20. NINDS. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008;31(3):141–50.
21. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschli M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67(7):1262–4.
22. NINDS. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664–71.
23. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society task force guidelines. Mov Disord. 2012;27(3):349–56.
24. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions Version 5.1.0. The Cochrane collaboration (Eds); 2011. p. 202–6.
25. Yusuf S, Petco Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
27. Bloom MR, NIH announces phase III clinical trial of creatine for Parkinson’s disease. Consult Pharm. 2007;22(5):378.
28. Xiao Y, Luo M, Luo H, Wang J. Creatine for Parkinson’s disease. Cochrane Database Syst. Rev. 2014;2014(6):CD009646.
29. Jonquel-Chevalier Curt M, Voicu PM, Fontaine M, Dessein AF, Porchet N, Mention-Mulliez K, et al. Creatine biosynthesis and transport in health and disease. Biochimie. 2015;119:146–65.
30. Ozotic SM, Ostojic J, Drid P, Vranes M. Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. Appl Physiol Nutr Metab = Physiologie appliquee, nutrition et metabolisme. 2016;41(9):1005–7.
31. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900–19.